A randomized study of de novo combination therapy lamivudine plus adefovir in HBeAg-positive chronic hepatitis B patients with genotype B/C
10.3969/j.issn.1006-5725.2015.07.008
- VernacularTitle:基因B／C型HBeAg（＋）慢性乙型肝炎患者初始拉米夫定、阿德福韦酯联合治疗疗效
- Author:
Huaie LIU
;
Jing YOU
;
Hongying CHEN
;
Jinghua FAN
;
Hua LIU
;
Ruyi ZHANG
;
Shaofeng RAO
;
Sijia MA
- Publication Type:Journal Article
- Keywords:
Hepatitis B,chronic;
Lamivudine;
Adefovir;
Combination therapy
- From:
The Journal of Practical Medicine
2015;(7):1065-1068
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy of de novo combination therapy lamivudine plus adefovir , lamivudine monotherapy and entecavir monotherapy in HBeAg-positive CHB patients with genotype B/C. Methods A total of 182 treatment-naive CHB patients in line with treatment standards of Chinese CHB prevention and treatment guidelines were randomly assigned to three groups and treated with lamivudine plus adefovir or lamivudine monotherapy or entecavir monotherapy for 48 weeks. Results Patients in three groups presented no difference in baseline levels. After treatment by three therapies , the group of lamivudine plus adefovir showed a higher biochemical response rates (12 week P < 0.01, 24 week P < 0.01, 48 week P < 0.01), HBeAg-serological rates(12 week P < 0.01, 24 week P < 0.05, 48 week P < 0.05) and completely virological response rates (12 week P < 0.05, 24 week P < 0.05, 48 week P < 0.05) than lamivudine group. In terms of biochemical response rates , the group of lamivudine plus adefovir had certain advantages when compared with entecavir group. Conclusion De novo combination therapy lamivudine plus adefovir is a good antiviral strategy for chronic hepatitis B patients with B/C genotype viral infection in China.
